AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$CSTL

Juvenal Tobin W sold $317K of CSTL

Juvenal Tobin W (Chief Commercial Officer) sold 9,050 shares of CASTLE BIOSCIENCES INC (CSTL) at $35.04 ($0.32M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Juvenal Tobin W
Published Aug 27, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale adds modest supply pressure but is pre‑arranged, limiting immediate market impact.

02

Market read

Primary relevance is to CSTL shareholders; broader market impact is negligible.

03

What to watch

Potential upcoming corporate events or financing needs not disclosed could be driving the sale.

Relevance 3/10Novelty 6/10Timing: post‑market 2026‑08‑25

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

Chief Commercial Officer sold 9,050 shares at $35.04 each, total $317,112 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as market digests sale.

Evidence & confidence

Sale size is modest relative to holdings, but execution under a 10b5‑1 plan suggests pre‑planned liquidity rather than panic.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and unlikely to shift sector sentiment.

Regional

No regional effect; transaction is company‑specific.

Global

Limited global relevance; only affects investors in CSTL.

Counterpoint

What could challenge this read

The sale could be routine liquidity, not a bearish signal; price may remain stable.

Key entities

  • Company
    Castle Biosciences Inc.

    Biotech firm developing diagnostic platforms; ticker CSTL.

  • Insider
    Juvenal Tobin W

    Chief Commercial Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min